Iniparib plus chemotherapy in metastatic triple-negative breast cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) exhibits DNA repair defects, making it a target for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors.
• PARP inhibition is a rational therapeutic strategy for TNBC due to its inherent DNA repair deficiencies.

Purpose of the Study:

• To compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib in patients with metastatic TNBC.
• To evaluate the impact of adding iniparib, a PARP inhibitor, to standard chemotherapy on clinical benefit and survival outcomes.

Main Methods:

• An open-label, phase 2 study involving 123 patients with metastatic TNBC.
• Patients were randomized to receive gemcitabine and carboplatin with or without iniparib every 21 days.
• Primary endpoints included clinical benefit rate and safety; secondary endpoints included objective response rate, progression-free survival, and overall survival.

Main Results:

• The addition of iniparib improved the clinical benefit rate from 34% to 56% (P=0.01) and the objective response rate from 32% to 52% (P=0.02).
• Median progression-free survival increased from 3.6 to 5.9 months (P=0.01), and median overall survival improved from 7.7 to 12.3 months (P=0.01).
• No significant difference in the rate of grade 3 or 4 adverse events was observed between the groups.

Conclusions:

• Adding iniparib to gemcitabine and carboplatin chemotherapy enhances clinical benefit and survival in metastatic TNBC patients.
• The combination therapy demonstrated improved efficacy without a significant increase in toxicity.
• A phase 3 trial is underway to further evaluate overall and progression-free survival outcomes.